Lumakras（sotorasib,AMG-510）

On May 29th, 2021, FDA announced that it would accelerate the approval of Lumakras(Sotorasib) for the treatment of patients with non-small cell lung cancer (NSCLC) whose tumor carries KRAS G12C mutation. These patients have received at least one early systemic treatment. This is the world’s first anti-cancer therapy targeting specific KRAS gene mutations.
Lumakras(sotorasib,AMG-510)_ Hong Kong Jimin Pharmaceutical

[Indications of Lumakras(sotorasib)AMG 510]
Lumakras is a prescription drug for the treatment of adult non-small cell lung cancer (NSCLC): non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery, and its tumor has abnormal KRAS G12C gene and has received at least one cancer treatment. Your doctor will test you to make sure Lumakras is right for you. It is not clear whether this drug is safe and effective for children.

[Warnings and Precautions of Lumakras(sotorasib)AMG 510]
1. Hepatotoxicity
Liver function (ALT, AST and total bilirubin) was monitored before Lumakras, once every three weeks for three months before treatment, then once a month or once according to clinical needs, and more frequent detection was performed in patients with elevated transaminase and/or bilirubin. According to the severity of adverse reactions, Lumakras should be kept, reduced or stopped permanently.
2. Interstitial lung disease (ILD)/ pneumonia
Monitor whether the patient has new or worsening lung symptoms (such as dyspnea, cough, fever), suggesting ILD/ pneumonia. Stop using Lumakras immediately for patients suspected of ILD/ pneumonia.

[contraindication of Lumakras(sotorasib)AMG 510]
without